A New Treatment Approach in Schizophrenia: What Real-World Use Can Teach Us

Schizophrenia is a complex psychiatric condition that can affect how a person thinks, perceives reality, experiences emotions, and functions day to day. While many people benefit from existing antipsychotic medications, others continue to experience symptoms despite multiple treatment attempts. This is often referred to as treatment-resistant schizophrenia, and it remains one of the most challenging areas in psychiatric care.

This article discusses themes from a recent peer-reviewed commentary by Dr. Richard Louis Price and Maxwell Zachary Price in Frontiers in Psychiatry. Their commentary focuses on xanomeline/trospium, also known as KarXT, and what early real-world clinical experience may teach clinicians about using newer psychiatric medications thoughtfully and safely.

Xanomeline/trospium has drawn attention because it works differently from many traditional antipsychotic treatments. Many commonly used antipsychotics primarily work through dopamine receptor activity. Xanomeline/trospium instead targets muscarinic receptors, which are part of the brain's cholinergic system. This difference is clinically meaningful because many patients with schizophrenia struggle not only with persistent symptoms, but also with side effects, incomplete response, or long-term limitations of existing medications.

The emergence of a medication with a different mechanism of action raises an important question: how should newer treatments be understood once they move from clinical trials into real-world practice? Clinical trials are essential for evaluating safety and effectiveness, but everyday psychiatric care is often more complicated. Patients may be taking several medications, have co-occurring medical or psychiatric conditions, experience difficulty with tolerability, or have histories of partial response to many prior treatments.

In their Frontiers in Psychiatry commentary, Dr. Price and Maxwell Zachary Price discuss how xanomeline/trospium may be used in real-world psychiatric practice, particularly for patients with treatment-resistant schizophrenia. Their article emphasizes that the success of a medication is not determined only by the drug itself. Timing, dosing strategy, food effects, co-prescribed medications, and side effect management can all shape whether a patient is able to tolerate and benefit from treatment.

This is especially important in treatment-resistant illness, where patients often have complicated histories of prior medication trials. When a patient does not improve, the reason is not always straightforward. A treatment may be ineffective for that person, but it is also possible that side effects, interactions, poor absorption, or the structure of the regimen affected the outcome. Careful review of these factors can help clinicians distinguish between a true lack of response and a treatment that may not yet have been optimized.

Another important takeaway is that tolerability can play a major role in whether a medication is clinically useful. Even when a treatment has potential benefits, side effects can make it difficult for patients to continue. In psychiatry, the goal is not simply to prescribe a medication, but to help a patient stay on a safe, appropriate, and effective treatment plan long enough to evaluate whether it is helping. That often requires education, monitoring, adjustment, and open communication between the patient and clinician.

The broader takeaway is that new psychiatric medications should be evaluated not only through clinical trial data, but also through careful clinical implementation. For patients with complex psychiatric conditions, progress often depends on thoughtful adjustment, close monitoring, and attention to the details of everyday use. As new treatment options emerge, clinicians will need to combine scientific evidence with practical judgment to understand where these therapies may fit in patient care.

Sources and Disclosures

This blog post discusses themes from the peer-reviewed commentary: Price MZ, Price RL. "Commentary: Real-world effectiveness and safety of xanomeline and trospium for treatment-resistant schizophrenia in a state hospital system." Frontiers in Psychiatry. Published March 9, 2026. doi: 10.3389/fpsyt.2026.1807080.

Funding: The authors of the original commentary reported that no financial support was received for the work or its publication.

Conflict of interest: Dr. Richard Louis Price, an author of the original commentary and a member of Rebu's clinical leadership, has served as a speaker for AbbVie, Alkermes, Allergan, Axsome, Biogen, Bristol-Myers Squibb, Idorsia, Intracellular, Janssen, Jazz, Lundbeck, Neuronetics, Otsuka, Sage, Supernus, Teva, and Vanda. The other author of the original commentary reported no commercial or financial relationships that could be construed as a potential conflict of interest.

Medical disclaimer: This blog post is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to recommend or promote any specific medication or treatment plan. Medication decisions should be made by a licensed clinician based on an individual patient's history, symptoms, risks, benefits, and clinical needs.